Study or Subgroup	ACE/ARB Mean	ACE/ARB SD	ACE/ARB Total	Placebo Mean	Placebo SD	Placebo Total	Weight	Mean difference IV, Random, 95% CI
Ahmad 1997 (a)	-5	13.6	37	-9	16.4	36	13.6%	4.00 [-2.92 , 10.92]
Ahmad 1997 (b)	-5	10.8	52	-5	13.5	51	17.9%	0.00 [-4.73 , 4.73]
Bojestig M 2001 (a)	-5	13.7	19	-6	18.6	16	8.1%	1.00 [-10.00 , 12.00]
Bojestig M 2001 (b)	4	13	18	-6	18.4	18	8.7%	10.00 [-0.41 , 20.41]
Crepaldi G 1998	-4	15.9	32	-5	13.4	34	13.3%	1.00 [-6.12 , 8.12]
Dragović T 2003	-22.3	24.5	10	-2	42.9	10	1.5%	-20.30 [-50.92 , 10.32]
Jerums G 2001	-11.1	5.9	13	-21	6.4	10	17.2%	9.90 [4.80 , 15.00]
Laffel LM 1995	4	26.6	67	-9	27.3	70	10.4%	13.00 [3.97 , 22.03]
Romero R 1993	-5	24.4	13	-5	39.5	13	2.1%	0.00 [-25.24 , 25.24]
Zandbergen AA 2003	-3	40.8	74	-2.4	32.9	73	7.2%	-0.60 [-12.57 , 11.37]
Total			**335**			**331**	**100.0%**	**4.34 [0.52 , 8.16]**



Test for overall effect: Z = 2.23 (P = 0.03)
Test for subgroup differences: Not applicable
Heterogeneity: Tau² = 15.35; Chi² = 16.94, df = 9 (P = 0.05); I² = 47%

Supplementary Figure 3: Effect of ACEIs or ARBs on improvement of GFR in diabetics